George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
From 210p to 12.1p in less than a year
But what about STRIVE? What about a free platform trial? What about US government? What about some abstract paper on interferons?
You pays your money and you takes your chances
Company are done, Marsden a total failure
So, now that 12p target price has been reached, no need for me to gloat, it’s been reached, end of
Do not throw your money at this stock now
You would be a total nugget to put more money in now
There is no free trial. There is no government funded trial, get this in to your brains
Biotech companies do not get given free trials. There are hundreds of small biotech companies in the world, most have multiple assets and they are in trials. Synairgen is a research company with a single asset and hasn’t had a trial for a year. That is a pile of sh111t when it comes to biotech
The only way they might get a trial is if they do a fund raise and finance it themselves, they might not even get enough money via a fundraise because people simply don’t want to throw money at this company, the management are a joke, the CEO is a failure
So they have their fund raise and the Shares are diluted further, the SP goes to 5p and below
If you want to take the gamble on this company because you believe in the science, that’s fine, take your punt, but just wait until the SP goes to 5p or below before you put your cash in
12p as predicted
What happened to STRIVE?
What happened to free trial?
You can say whatever BS you want to say, but 12p was my target price and now it has been reached.
On to the next prediction. Fund raise needed and SP to fall below 5p
Look back at the optimistic upbeat post.
‘Not long now before great news’
Hmm SP is now 12p
Let’s be real for a change, instead of patting each other on the back, Synairgen zealots are just full of total sh111t
dunk, why did you buy more at 11p?
You’ve been told it’s going to 5p.
You should buy when it goes to 5p instead.
You were told it would go to 12p, you didn’t listen, you ramped. You bought in at 24p, then it flumped 50% again. Now you’re being told it will go to 5p and you’re buying in at 12p, why?
There is no free trial, only a fund raise to come. Synairgen probably won’t even be able to raise enough funds to finance a trial anyway. 5p and below is incoming.
You’ve just thrown away your money today
As posted previously numerous times, the 12p will be achieved.
The rampers on here (with their total BS) kept ramping, mentioning trials continuously, it was all a load of tosh, but sadly many people got suckered in.
What do you have to say for yourselves rampers?
Synairgen zealots blindly supporting this lump of rubbish.
12p is just the start.
Remember what I wrote, fund raise to come in order to keep the company afloat.
5p incoming
As I wrote in a more detailed post earlier, the target price is 12p.
The more this company, with one single asset and zero trials waits and waits and waits for a free trial to be put on, the more the SP will decline.
Most small biotech companies out there have multiple assets and ones that are actually in trials. It is extremely rare for a single asset company to not even have its drug on a trial for the best part of an entire year now.
Marsden and the others have been ‘working at haste’, well it’s clear to anyone that they just a pretty rubbish at their jobs. They haven’t secured a free trial for their single asset in 11 months.
This leaves two scenarios, either FUND RAISE in order to raise enough funds for their own trial. They might not even be able to raise enough funds for a new trial (there might not be the appetite) in which case the company will just use up the cash on fat salaries and then call it a day in a couple of years.
If they do raise enough capital from a fund raise then the SP will go down a further 50% due to share dilution.
We can expect a constant downward trend to the SP until any news of a fund raise is given. I predict 12p, followed by a swift return to 5p once fund raise is announced.
If however, miraculously this company, after 11 months of ‘working at haste’ manages to get on a free trial (let’s be honest, looks pretty unlikely), then you could see 50p and more.
What’s the likelihood of them getting on a free trial, given that they’ve been working at haste for the last 11 months and got absolutely nothing to show for it?
It begs the question, what have the staff even been doing at this company for a year?
Anyway, TP of 12p, then TP of 5p after the fund raise.
The usual mob of Synairgen zealots will start wailing and cursing, but they’ve been consistently wrong every single time so far.
I have one question though, what happened to STRIVE??
Apparently Synairgen was going to be on STRIVE according to the zealots here? First it was June, then July, then September.
Ahem, let’s be real, it’s gonna be fund raise or bust for this single asset company. No drug, no trial, nothing to take to market. Bye bye Synairgen.
I forgot, there are two further possibilities:
5. After the SP falls to 4-6p directly after share dilution in order to finance their own P3 trial again, either the new P3 trial works and Synairgens only drug passes the P3 trial and they have a product to sell.
In this scenario the SP rises to £5 (would have been higher, but due to the dilution from the fund raise and outstanding shares, the price is lower than it previously would have been had SPRINTER been a success).
Or their own P3 trial fails again, which would most likely spell the complete end of the company, but giving Marsden and some other employees a nice salary for the next 4 or more years until their retirement with a fat pension. In this scenario Synairgen are bankrupt and their single drug fails to ever get on the market.
6 possibilities, two of them show a path to a good future for the company, but four do not.
Synairgen either needs to get on a free trial (again, I reiterate, it has taken 11 months of ‘working at haste’ and there is no news as of yet of a place on a free trial), or they must have a fundraise and raise the capital to run their own P3 trial.
Price targets and possible scenarios with Synairgen:
1. Synairgen somehow manages to get on to a free trial, after 11 months of ‘working at haste’ Marsden the CEO finally manages to get Synairgen on to a free government ran trial.
In this scenario the target price will be 50p or higher.
Obviously a year or two down the line the 50p initial price will turn in to multiples if Synairgen’s drug (and only drug in their pipeline) passes the free trial.
But in order for this to happen, Synairgen must be offered on to a free trial first. This is unlikely because covid is far milder than it used to be and the urgency for new treatments just isn’t there. The fact that it has taken 11 months already and there is no news speaks volumes.
2. No free trial. In this scenario the SP will slowly decline as it has been doing gradually with no news for months. We probably see the SP decline to around 12p.
3. Once at 12p, Synairgen are forced to make a decision. They tried to get on to a free trial, but failed, therefore they must do what every other biotech company does (and what they did in 2020) and have a fund raise.
With a fund raise this means the SP will decline because the outstanding shares will be diluted, in this scenario we see the 4-6p range emerge.
4. Finally, there is the possibility that Synairgen do not raise enough capital from their fundraise for a new P3 trial. So they decide to use the fund raise to simply pay off inflated and fat wages to the CEO/other staff, maintaining the business wages similar to a charity but leeching off shareholder money. Synairgen are a single asset company and that asset is a failed drug which needs to pass a P3 trial before they can be called a business. In this scenario we see Synairgen never getting their single drug to market (the CEO has failed for 20 years so far) and they use up the shareholders money then retire on fat pensions, the end of the company.
Best wishes for the holidays
Drew
Commiserations to your soccer team. You played the better football but couldn’t clinch the winning goal.
Rather reminiscent of Synairgen. Had a complex trial set up, but never really went for the jugular.
There’s always next World Cup
syn can also do a fund raise and fund their own trial again, but the share price will tank on the news of a fund raise.
There is no free trial looming, it doesn’t take a company 11 months to search for a free trial if there was one available. The company are clutching at straws and they know a fund raise is needed to pursue development of their single asset.
Anyone who actually believes that the team at Synairgen are earning a proper days work need to have their heads examined. They have enough cash to keep their cushty jobs and keep the company running for another two years, that could see Marsden up to retirement, then it’s time to fold the company for good.
Zero urgency, missed the boat with covid, designed a horrendously flawed trial, sit there for 11 months ‘working at haste’ to find a free handout.
In Italy we have a saying, la dolce vita, be thankful for the sweet life. My last remaining two days in satorini and what a beautiful island it is
Forget this stock, a big weight will be erased from your shoulders, it’s done.
I will be watching from Santorini
We are supporting England over France
I think that England have a much higher chance of winning the soccer World Cup than Synairgen have.
England’s chance = 40% chance of winning World Cup
If they win today then I think 80% chance
Synairgens chance = 20% chance of getting on free trial, 80% chance of needing new fund raise and SP falling to below 10p again.
Enjoy the soccer match
Sure something is going on, the SP fell by over 8%
People realise that soon enough a fund raise will be needed and plenty of share dilution will occur.
There is no free trial (Synairgen have taken ten months already to organise a free trial and after ten months are still unsuccessful).
It really doesn’t take ten months to get on a free trial. If there was a trial which this drug would be invited on to, it would have happened by now.
Therefore fund raise is needed = huge share dilution to generate funds for new trial = large fall in SP due to come.
Target price 12p.
Plenty of people were touting STRIVE in June, then July, then August, but definitely by September.
When members told these rampers that this was tosh, those members were hounded by the usual rampers.
Well well well, we are now in December. Ten months on from the calamity that was SPRINTER. Yet no sign of being included on any free trial.
Remember, no free trial = Synairgen must fund their own trial = fund raise = large number of shares offered = large fall in SP.
Serious questions need to be asked, such as what is the CEO and board doing every day? Have plans been put in place and a new designed trial ready to roll out as soon as announced? Hmmmm, I very much doubt it. If they are, there has been absolutely zero communication to the shareholders.
What is the need for a research company that doesn’t research anything? There are no trials or development being done right now on Synairgens single asset. Nothing has been done for the last ten months.
Hmmm
I’ve wondered, Synairgen has one potential drug.
Their P3 trial failed miserably 10 months ago and they apparently have been working ‘at haste’ to get on a new free trial.
However within those 10 months, so far they have not succeeded to get on to a free trial.
Let’s be honest, they’re going to need a fund raise to raise the capital to do their own trial again.
However, how does this compare to other biotech firms? If anyone remembers NRX pharma, they have multiple drugs in their potential pipeline. Most of which are in current trials.
It seems worrying that Synairgen have one failed drug and it isn’t even on any sort of trial (afterall, they are a biotech company) for almost a year now.
What exactly have management been doing? Without a trial, the interferons are completely and utterly useless.
It’s pretty clear there is no free trial on offer. So the next stop is to do what every other small biotech company does and have a fund raise. In order to raise the capital for a new P3 trial there will be plenty of dilution, so expect the SP to fall down accordingly, another 40/50% upon dilution due to a new offering.